Advertisement
ResearchIn-Press PreviewDevelopmentGastroenterologyOncology
Open Access |
10.1172/JCI197772
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Singh, P. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Hadj Bachir, E. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Howe, J. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Bellizzi, A. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by
Cejas, P.
in:
PubMed
|
Google Scholar
|
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Madha-Krause, S. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Epstein, C. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Chan, J. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Bernstein, B. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Kulke, M. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Zhou, Q. in: PubMed | Google Scholar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America
3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America
6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America
Find articles by Shivdasani, R. in: PubMed | Google Scholar
Published May 21, 2026 - More info
Cancers reflect aberrant growth and differentiation of normal cell populations. Biological understanding of small intestine neuroendocrine tumors (SI-NETs) is hampered because their closest normal counterparts, enteroendocrine cells (EECs), constitute tiny fractions of intestinal epithelium. Recent characterization of adult human EEC ontogeny from intestinal stem cells can help overcome that limitation. Transient expression of transcription factor gene ASCL1 normally ensures proper timing and fidelity of well-differentiated EECs, which express NEUROD1. Here we report that SI-NETs resembled mature enterochromaffin cells; however, individual tumor cells co-expressed stem/progenitor genes, harboring each differentiation state along the EEC trajectory except ASCL1+ precursors. We found that enhancers normally active, and others inactive, during EEC differentiation underlie aberrant SI-NET gene activity. SI-NETs uniformly expressed NEUROD1 but lacked ASCL1, owing to inaccessible chromatin and repressive H3K27me3 marking at the ASCL1 locus. Multiple cyclin-dependent kinase inhibitor (CDKi) genes were similarly silenced, other than CDKN1B, the only gene recurrently mutated in SI-NETs. Deletion of CDKN1B altered cell cycle kinetics during human EEC differentiation, and deletions of ASCL1 or CDKN1B activated certain genes that are expressed in SI-NETs but not in the normal EEC trajectory. We propose that a limited CDKi repertoire and absence of ASCL1-dependent constraints on EEC maturation together explain unique SI-NET characteristics.